IJIRCCE

ISSN(O): 2320-9801

ISSN(P): 2320-9798



International Journal of Innovative Research in Computer and Communication Engineering

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)





Impact Factor: 9.927

Volume 14, Issue 5, May 2026

© 2026 IJIRCCE | Volume 14, Issue 5, May 2026 DOI: 10.15680/IJIRCCE.2026.1405017

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 9.927| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

AI for Early Detection of Neurological Diseases: A Comprehensive Review

Prof. Manjula P[1], Sinchana T[2], Suhasini T R[2], Rekha V N[2], Sandeep M[2], Vikash K N[2], Syed Sadath H[2]

Assistant Professor, Dept. of CSE, Jain Institute of Technology, Davangere, Karnataka, India[1]

UG Students, Dept. of CSE, Jain Institute of Technology, Davangere, Karnataka, India[2]

ABSTRACT: Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease pose considerable global health challenges, marked by progressive neuronal degeneration and functional deterioration. Conventional diagnostic methods frequently detect these conditions only subsequent to significant and irreversible cerebral damage, thereby constraining therapeutic effectiveness. This review investigates the transformative impact of artificial intelligence (AI) in facilitating the earlier identification of neurological disorders through the analysis of multimodal data sources. We combine the latest improvements in machine learning and deep learning for use in neuroimaging, speech patterns, gait analysis, retinal imaging, and clinical data integration. Recent studies show that multimodal AI models consistently do better than single-modality models. For example, they can identify Alzheimer's disease with 92.5% accuracy. New methods like explainable AI, federated learning, and anomaly detection frameworks are helping to solve important problems with model interpretability, data privacy, and finding early prodromal signatures. This review ends by pointing out the current problems and suggesting ways to move forward with putting AI-based diagnostic tools into clinical practice.

KEYWORDS: Neurodegenerative diseases, artificial intelligence, early detection, machine learning, multimodal data integration, explainable AI, Alzheimer's disease, Parkinson's disease.

I. INTRODUCTION

Neurodegenerative diseases include a number of progressive disorders that slowly kill neurons, making it harder to move, think, and talk. Alzheimer's disease impacts around 50 million individuals worldwide, whereas Parkinson's disease ranks as the second most prevalent neurodegenerative disorder globally. These conditions usually develop slowly over many years without any obvious signs, leaving a crucial time when early intervention could have a big impact on the course of the disease.

The pathophysiological processes that cause neurodegeneration, such as protein aggregation, synaptic dysfunction, and neuronal death, often start decades before a doctor can make a diagnosis. Amyloid-beta buildup can be found 15 to 20 years before symptoms of Alzheimer's disease show up. Likewise, the pathology of Parkinson's disease, marked by alpha-synuclein aggregation, commences years prior to the onset of motor symptoms. This extended presymptomatic phase poses both a challenge and an opportunity: conventional diagnostic approaches that depend on clinical examination and structural imaging generally identify issues only after significant brain damage has transpired, whereas early detection could facilitate prompt intervention and enhanced outcomes.

Artificial intelligence has become a game-changer in medical diagnostics by being able to look at complex, high-dimensional data and find patterns that human experts can't see. Machine learning algorithms can combine different types of data, such as neuroimaging, genetic information, speech recordings, wearable sensor data, and electronic health records, to find early signs of neurodegeneration. Recent systematic reviews have shown that multimodal AI models are always better than single-modality models. For example, the Alzheimer's Disease Neuroimaging Initiative-based diagnosis had an average accuracy of 92.5%.

This review provides a comprehensive examination of AI applications for early neurological disease detection. We survey current methodologies, analyze key findings from recent studies, discuss technical and clinical challenges, and propose future research directions.

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 9.927| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

II. BACKGROUND AND CLINICAL CONTEXT

2.1 The Challenge of Early Diagnosis

Finding neurological diseases before symptoms appear is a tough task. There are a few reasons for this. Firstly, the early signs of these diseases are often very slight and can be mistaken for normal changes that happen as we age. Secondly, some conditions that happen before the main disease appears, like mild cognitive impairment in Alzheimer's or REM sleep behavior disorder in Parkinson's, might not be recognized as warning signs. Lastly, getting access to special tests that can help diagnose these diseases, such as looking at the fluid around the brain and spine or using a special kind of imaging test, can be difficult because they are expensive, invasive, or not widely available. This makes it hard to detect these diseases early on, which is important for getting the right treatment and care.

Traditional diagnostic workflows rely heavily on clinical neurological examinations, cognitive assessments, and structural imaging. While these approaches remain valuable, they typically identify diseases only after significant neuronal loss has occurred. For Alzheimer's disease, structural magnetic resonance imaging reveals hippocampal atrophy only after substantial neurodegeneration. Similarly, Parkinson's disease diagnosis remains primarily clinical, with confirmation often delayed until motor symptoms are unequivocal.

2.2 The Promise of AI-Based Detection

AI offers several advantages for early neurological disease detection. Machine learning algorithms can integrate heterogeneous data types, identify nonlinear relationships, and discover novel biomarkers. Deep learning architectures, particularly convolutional neural networks, excel at extracting hierarchical features from imaging data. Natural language processing enables analysis of clinical notes and speech patterns. Time-series models can detect subtle changes in gait, typing patterns, or smartphone usage that may precede clinical diagnosis.

Recent advances have demonstrated AI's potential across multiple modalities. Deep learning models applied to retinal fundus images can identify structural and vascular changes associated with Alzheimer's and Parkinson's diseases, offering a non-invasive screening approach. Transformer-based architectures have achieved state-of-the-art performance in detecting neurological diseases from electroencephalography signals, processing up to 250 frames per second with high accuracy.

III. AI METHODOLOGIES FOR NEUROLOGICAL DISEASE DETECTION

3.1 Machine Learning Approaches

Traditional machine learning algorithms are still the basis for detecting many neurological diseases. Some methods, like support vector machines, random forests, and gradient boosting, work really well with structured clinical data. This kind of data includes things like cognitive assessment scores, demographic information, and genetic markers. These models have some big advantages: they don't need as much computing power as deep learning approaches, they're easier to understand, and they can work well even with small amounts of data. This makes them really useful for certain applications. They're also good at handling data that's already organized, like the kind you'd find in medical records. Overall, these traditional machine learning algorithms are still a great choice for many neurological disease detection tasks.

Decision tree-based algorithms, including random forests and XGBoost, have demonstrated success in identifying prodromal Parkinson's disease from clinical and wearable sensor data. These methods can handle mixed data types, manage missing values, and provide feature importance rankings that inform clinical understanding. Logistic regression and support vector machines remain valuable for binary classification tasks, such as distinguishing mild cognitive impairment converters from stable patients.

3.2 Deep Learning Architectures

Deep learning has revolutionized neuroimaging analysis. Convolutional neural networks automatically learn hierarchical features from structural and functional imaging data, eliminating the need for manual feature extraction. Three-dimensional CNNs can process volumetric MRI data directly, capturing spatial patterns associated with neurodegeneration. These models have achieved high accuracy in distinguishing Alzheimer's disease from normal aging and frontotemporal dementia.

Recurrent neural networks and transformer architectures excel at analyzing sequential data, including speech recordings, gait patterns, and time-series physiological signals. The recently developed Lightweight Self-Attention based on Deep Gated Network (LSA-DGNet) combines multi-scale time-aware self-attention modules with deep gated neural networks, achieving state-of-the-art performance in multiple neurological disease detection from EEG signals.

Generative models including variational autoencoders and generative adversarial networks have enabled novel approaches to anomaly detection. The "pseudo-healthy twin" concept uses generative models to create synthetic, personalized baselines from structural data such as MRI, enabling identification of disease-specific effects by subtracting normal anatomical variability.

3.3 Multimodal Data Integration

Multimodal AI models that integrate complementary data types consistently outperform unimodal approaches. A systematic review of 66 studies found that multimodal models achieved average diagnostic accuracy of 92.5% for Alzheimer's disease, compared to lower performance for single-modality models. Fusion strategies include early fusion (combining raw data before feature extraction), intermediate fusion (integrating features from separate modality-specific encoders), and late fusion (combining independent model predictions).

The CogNID study takes a thorough approach by combining several methods, including tests of cognitive function, MRI scans, clinical biomarkers, and radiology reports. It uses natural language processing, specifically PubMedBERT, to identify risk contexts from written reports. At the same time, FSL software is used to extract volumetric features, such as measurements of medial temporal and global cortical atrophy. All these features are then combined and processed using ensemble methods and neural networks to classify diseases. This fusion of different types of data and analytical techniques helps to provide a more complete understanding of the disease. By integrating these various components, the study aims to improve disease classification and potentially lead to better patient outcomes.

Retinal imaging is a new way to detect diseases that affect the brain without being invasive. This is possible because the retina and the central nervous system have a common origin and share some features. Changes in the retina can indicate problems in the brain. Using special tools like optical coherence tomography and fundus photography, doctors can see if the nerve fiber layer in the retina is thinning, if ganglion cells are dying, or if there are problems with the blood vessels. These changes are often linked to Alzheimer's and Parkinson's diseases. Computers can be taught to look at retinal images and spot these changes, which could help with early detection. However, more research is needed to confirm this in a large number of people.



www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 9.927| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

IV. KEY APPLICATIONS AND RESEARCH FINDINGS

4.1 Alzheimer's Disease Detection

Alzheimer's disease is getting a lot of attention from researchers who are using artificial intelligence to detect it. They are using a combination of different methods, including MRI scans, PET scans, and tests of the fluid around the brain and spine, as well as assessments of cognitive function. By combining all these different methods, they have been able to accurately diagnose Alzheimer's disease in many cases. In fact, a recent analysis of many studies found that using machine learning to look at markers of small vessel disease in the brain was very effective in telling the difference between healthy people and those with Alzheimer's dementia, with an accuracy rate of 88%. This is a significant finding, and it suggests that AI-based detection methods may be a useful tool in the fight against Alzheimer's disease.

Explainable AI methods have been developed to enhance the clinical utility of Alzheimer's disease detection models. A recent study trained convolutional neural networks on brain MRI scans from 3,253 participants across six international cohorts, implementing multiple explanation approaches including model simplification, explanation-by-example, and textual explanations. Clinician evaluation confirmed that these explanations enhanced diagnostic efficiency and trustworthiness.

4.2 Parkinson's Disease Detection

Parkinson's disease detection has benefited from AI analysis of motor and non-motor features. Machine learning models applied to smartphone accelerometer data can detect subtle gait and tremor abnormalities before clinical diagnosis. Speech analysis using deep learning identifies characteristic vocal changes including reduced volume, monopathy, and articulatory imprecision. Retinal imaging studies have identified alpha-synuclein-related spectral signatures using hyperspectral imaging, though these techniques remain experimental.

4.3 Presymptomatic Detection and Anomaly Identification

A critical frontier is detecting neurological disease before any recognized prodromal syndrome emerges. Traditional supervised learning approaches require predefined labels, limiting their ability to identify truly presymptomatic individuals who have not yet developed mild cognitive impairment or REM sleep behavior disorder.

V. IMPLEMENTATION RESULTS AND SYSTEM DEMONSTRATION



www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 9.927| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)



VI. CHALLENGES AND LIMITATIONS

6.1 Generalizability and External Validation

A major limitation of current AI-based detection systems is limited external validation. Most studies are conducted on single-center datasets with specific inclusion criteria, scanner protocols, and population demographics. Performance often degrades substantially when applied to independent datasets from different institutions or populations. Among 75 studies examining machine learning for neurodegenerative disease classification, only five assessed generalizability on external datasets.

6.2 Data Scarcity and Class Imbalance

High-quality multimodal datasets require substantial resources for acquisition and annotation. For rare neurodegenerative diseases and prodromal stages, data scarcity is particularly severe. Class imbalance—where disease cases are

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 9.927| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

substantially fewer than controls—can bias models toward high specificity at the expense of sensitivity. Federated learning approaches that enable model training across institutions without sharing patient data offer a promising solution.

6.3 Interpretability and Clinical Trust

Healthcare providers require interpretable predictions to trust and act upon AI recommendations. While post-hoc explanation methods including saliency maps, SHAP values, and LIME have been developed, their clinical validity remains debated. Different explanation methods can produce conflicting interpretations for the same prediction. Furthermore, explanations that satisfy technical criteria may not align with clinical reasoning or biological understanding.

6.4 Ethical and Regulatory Considerations

Deploying AI for neurological disease detection raises ethical concerns regarding data privacy, algorithmic bias, and appropriate use. Patients identified as at-risk may experience psychological distress from prognostic information without available disease-modifying therapies. Regulatory approval pathways for AI-based diagnostic tools remain evolving, with requirements for prospective validation and continuous performance monitoring.

VII. FUTURE DIRECTIONS

7.1 Advancing Multimodal Integration

To take research to the next level, we need to create strong frameworks that can handle different types of data and deal with missing information, which is a common issue in clinical settings. One way to do this is by using hybrid architectures that combine generative and discriminative models, as this could lead to better performance and more robust results. Additionally, using intelligent sensor fusion approaches could help us find new early biomarkers by analyzing combinations of data that haven't been considered before. This could be a game-changer in identifying potential health issues early on. By exploring these new approaches, we can make significant progress in improving clinical outcomes and patient care.

7.2 Explainable AI for Clinical Decision Support

To really make explainable AI methods work in clinical settings, we need to focus on making them more valid and useful. This means we should test how well these explanations match up with what clinicians think and what we know about biology, rather than just looking at technical numbers. We also need to make sure these explanations fit into the way clinicians work and are tailored to their level of expertise.

7.3 Longitudinal and Personalized Prediction

Most current models provide cross-sectional classification rather than personalized predictions of disease progression. Longitudinal models that incorporate multiple timepoints could predict individual trajectories, enabling risk stratification and clinical trial enrichment. Integration of genomic, proteomic, and other -omic data may enable precision medicine approaches tailored to individual pathophysiology.

7.4 Translation to Clinical Practice

Accelerating translation requires standardized evaluation benchmarks, prospective validation studies, and integration with clinical workflows. Collaboration among AI researchers, clinicians, regulatory bodies, and patient advocacy groups is essential to establish guidelines for development, validation, and deployment of AI-based diagnostic tools.

VIII. CONCLUSION

Artificial intelligence is changing the way we detect neurodegenerative diseases early on. It's helping us analyze complex data from different sources, like brain scans, speech, walking patterns, eye scans, and medical records, to find tiny signs of disease. By using machine learning and deep learning, we can spot these signs with accuracy that's as good as, or even better than, human experts. When we combine data from multiple sources, we get better results than when we use just one source. In fact, studies have shown that this approach can diagnose Alzheimer's disease with an average accuracy of 92.5%. New techniques are also being developed to help us find diseases before symptoms appear, keep patient data private, and make sense of the results for doctors. These new techniques include anomaly detection, which helps us find unusual patterns in the data, federated learning, which lets us train AI models on data from different sources without sharing the actual data, and explainable AI, which helps us understand how the AI models are making their predictions. All these advances are critical to making AI a powerful tool in the fight against neurodegenerative diseases.

© 2026 IJIRCCE | Volume 14, Issue 5, May 2026 DOI: 10.15680/IJIRCCE.2026.1405017

www.ijircce.com | e-ISSN: 2320-9801, p-ISSN: 2320-9798| Impact Factor: 9.927| ESTD Year: 2013|

International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

There are still some big problems to solve. We don't have enough outside validation, we're missing data on rare conditions, and we're not paying enough attention to how our models work. To fix these problems, we need to do some rigorous studies, create standards for evaluating our models, and develop methods that explain how our models work in a way that makes sense to clinicians. If we can do this, we can unlock the potential of AI-based neurological diagnostics. As healthcare moves towards preventing diseases and tailoring treatments to individual patients, AI-based early detection systems will become really powerful tools for improving neurological care. They'll help us catch diseases earlier, get better outcomes, and understand how diseases work at a deeper level.

IX. SUMMARY OF KEY CONTRIBUTIONS

This study has brought together the latest information on how artificial intelligence can be used to detect neurological diseases early on, and it has made some important points, including:

1. **Comprehensive methodology survey:** We have reviewed machine learning, deep learning, and multimodal integration approaches applied to neurological disease detection, highlighting relative strengths and limitations.
2. **Critical evaluation of current evidence:** Drawing on recent systematic reviews and meta-analyses, we have quantified diagnostic performance across modalities and identified factors influencing generalizability.
3. **Identification of emerging techniques:** We have highlighted novel approaches including pseudo-healthy twin models, anomaly detection frameworks, and explainable AI methods that address current limitations.
4. **Analysis of challenges and solutions:** We have systematically examined barriers to clinical translation including external validation, data scarcity, and interpretability, identifying potential solutions.

REFERENCES

[1] Dang, M., et al. (2026). Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine. Psychoradiology, 6, kkag007. https://doi.org/10.1093/psyrad/kkag007

[2] Yu, Z., et al. (2026). Multimodal AI for Alzheimer Disease Diagnosis: Systematic Review of Datasets, Models, and Modalities. Journal of Medical Internet Research, 28, e85414. https://doi.org/10.2196/85414

[3] CogNID Study Group. (2025). AI-Driven Pipeline for Analysis and Classification of Neurodegenerative Diseases from Cognitive, Imaging, and Clinical Biomarkers. Alzheimer's & Dementia, 21(Suppl 1), e106908. https://doi.org/10.1002/alz70855_106908

[4] Soulier, T., et al. (2025). Artificial intelligence in presymptomatic neurological diseases: Bridging normal variation and prodromal signatures. Revue Neurologique, 181(9), 944-950. https://doi.org/10.1016/j.neurol.2025.07.011

[5] Jain, S., et al. (2025). Lightweight self-attention and deep gated neural network (LSA-DGNet) for multiple neurological disease detection. Computers in Biology and Chemistry, 120(Pt 1), 108621. https://doi.org/10.1016/j.compbiolchem.2025.108621

[6] Retinal biomarkers for Alzheimer's and Parkinson's diseases using advanced imaging and artificial intelligence. (2026). In Advances in Clinical Chemistry. https://doi.org/10.1016/bs.acc.2026.01.010

[7] Lohner, V., et al. (2025). Machine learning applications in vascular neuroimaging for the diagnosis and prognosis of cognitive impairment and dementia: a systematic review and meta-analysis. Alzheimer's Research & Therapy, 17. https://doi.org/10.1186/s13195-025-01815-6

[8] Singh, D., et al. (2025). An unsupervised XAI framework for dementia detection with context enrichment. Scientific Reports, 15(1). https://doi.org/10.1038/s41598-025-94689-1

[9] World Health Organization. (2020). Neurological Disorders: Public Health Challenges. Geneva: WHO Press.

[10] Alzheimer's Association. (2023). Symptoms and Diagnosis of Alzheimer's Disease. Chicago: Alzheimer's Association.

[11] Parkinson's Foundation. (2022). Understanding Parkinson's Disease. Miami: Parkinson's Foundation.

[12] Pedregosa, F., et al. (2011). Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research, 12, 2825-2830.